iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Yes, distributed drug discovery can help neglected diseases—but a screening hit is only a starting point. In the most useful models, universities, teaching laboratories, non-profits, pharmaceutical companies and compound-library owners contribute different pieces: chemical structures, new synthesis, screening capacity, computational analysis, data or funding. The result is a larger and less duplicated search for leads, followed by the same demanding optimization, safety testing and clinical development required of any medicine.
What “crowdsourced drug discovery” means in practice
The phrase does not describe one universal contest in which anyone uploads a molecule and waits for a cure. It is better understood as a range of distributed collaborations. One project may publish compound identities and protocols; another may ask teaching laboratories to make molecules designed by a coordinating organization; a third may let companies screen their private libraries under agreed rules.
DNDi’s Open Synthesis Network illustrates the teaching-laboratory model. Chemistry classes at more than 20 participating institutions contribute synthesis work, making compounds that DNDi can test for anti-parasitic activity. The institutions are part of a coordinated program, not independent clinics claiming to test treatments. DNDi describes the network and its drug-discovery workflow on its Drug Discovery page.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitchesOther arrangements can be more transparent about data or compound provenance without being fully open to the public. The relevant questions are: who contributes, what is shared, who controls intellectual property, which disease and assay are being used, and how far a molecule has progressed.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
Why neglected diseases benefit from distributed work
Neglected diseases often have a severe mismatch between health need and commercial incentive. DNDi was established to address research-and-development gaps and coordinates projects with public-sector groups, academic laboratories, pharmaceutical companies and other partners, as explained in its “Who we are” description.
A historical measure shows the scale of that gap without pretending it is a current global estimate. DNDi’s 2013 analysis reported that, from 2000 to 2011, 4% of new drugs and vaccines approved for all diseases addressed neglected diseases, compared with an 11% health burden; it also reported that 1% of new drugs were for neglected diseases. Those figures are specific to the period and definitions used in that 2013 report, not a 2026 approval rate. The report is available at DNDi’s 10-year analysis.
Distributed collaboration can add scientists to a field that otherwise has too few active projects and can reduce repeated experiments. DNDi states: “Science works through sharing and collaborating, and doing so can notably attract additional world-class researchers to a neglected field, enabling better results, faster and cheaper by reducing duplication.” That is an institutional rationale, not a guarantee that every open project will be faster or less expensive.
Free tools Windows power users keep installed
One-click scans. No signup required.
DNDi’s executive director Dr Luis Pizarro framed the stakes in the organization’s 2025 annual report: “Developing the medicines that neglected communities have gone without for generations is a lifeline, not a luxury that can wait for easier times or be traded away for short-term savings.” The statement appears in “A pipeline of promise”.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
How a compound moves from a screen to a medicine
Screening and clinical treatment are separated by several decision gates. A credible crowdsourced project should make clear which gate it has reached.
- Define the biological question. Investigators choose a pathogen, disease-relevant strain, molecular target or cellular assay, and a measurable activity threshold. A molecule active in one assay may be irrelevant to another disease or target.
- Run a primary screen. A collection is tested at scale to find “hits”—compounds that meet the assay’s initial activity criteria. DNDi says it has screened more than 3 million compounds for Leishmania and Trypanosoma cruzi, and 1.5 million for Trypanosoma brucei. These are cumulative figures on DNDi’s current Drug Discovery page; the page text does not provide a publication year, so they should not be read as an annual 2026 total.
- Confirm and triage hits. Re-testing, counterscreens and checks for assay interference help determine whether activity is reproducible and biologically meaningful. A hit can fail because it is toxic to host cells, chemically unstable, insoluble or active only under an artificial test condition.
- Evaluate a lead series. Related molecules are compared to identify structure–activity patterns, selectivity and properties that can be improved. This is where a single interesting result becomes a tractable chemical program.
- Optimize the lead. Medicinal chemistry may seek better potency, exposure, stability, formulation and safety margins while preserving activity against the intended pathogen. DNDi describes screening, lead evaluation and optimization as parts of its discovery process.
- Nominate a preclinical candidate. A candidate must meet a broader package of pharmacology, toxicology, manufacturing and animal-study requirements. “Promising” in a plate assay is not the same status.
- Conduct clinical studies and seek approval. Human trials assess dosing, safety and efficacy in the disease population. Regulatory authorization and reliable manufacturing and access plans are separate achievements.
Because failures can occur at every transition, neither a large library nor an open data policy proves that a treatment exists. Claims should identify the exact molecule, disease, assay and development stage.
DNDi initiatives that show different collaboration structures
Open Synthesis Network: distributed chemistry teaching
The Open Synthesis Network uses chemistry teaching laboratories to design and make compounds for DNDi to test for anti-parasitic activity. DNDi reports participation from more than 20 institutions. The contribution is new synthesis and practical training inside a coordinated network; it is not an assertion that every student laboratory independently discovers or validates medicines. The project is described at DNDi’s Drug Discovery page.
This arrangement can expand the number of chemists working on neglected pathogens and produce analogues that would not otherwise be made. DNDi still performs the biological testing and downstream selection, so the network’s output should be described as compounds entering a screening and optimization pipeline.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Mycetoma Open Source: a transparent, community-driven effort
Mycetoma is a chronic fungal disease for which treatment options and commercial incentives have been limited. DNDi describes its Mycetoma Open Source project as transparent and community-driven. The model emphasizes sharing and participation around a defined disease problem, but the cited descriptions do not say that every protocol, compound, patient-level dataset or intellectual-property right is unrestricted. Readers should distinguish “open source” as a project commitment from a claim that all materials are immediately public.
The initiative is discussed in DNDi’s Drug Discovery material and its 2025 open-science policy report, DNDi Open Science in a Closed World.
NTD Drug Discovery Booster: coordinated company screening
Launched in 2015, DNDi’s NTD Drug Discovery Booster allowed participating pharmaceutical companies to screen millions of compounds simultaneously. The arrangement did not impose one universal ownership rule: commitments concerning resulting hit compounds depended on whether the seed compounds came from the public domain or DNDi, or were owned by a participating company. This is a useful contrast with teaching-lab synthesis. It shows that “crowdsourced” can mean synchronized industrial capacity while keeping different intellectual-property terms for different starting materials.
Pathogen Box: a shared collection with a data expectation
DNDi’s 2025 policy report says the Medicines for Malaria Venture Pathogen Box gives researchers free access to 400 compounds active against bacteria, viruses or fungi. The arrangement includes an expectation that data generated with the collection will be shared in the public domain within two years. Free access to a compound collection lowers an entry barrier; it does not establish that any particular compound treats mycetoma, leishmaniasis, Chagas disease or another neglected disease.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
The 400-compound description and the two-year data-sharing expectation are in DNDi’s 2025 open-science policy report.
Acoziborole: reusing a starting point without promising a shortcut
DNDi’s 2025 annual report says acoziborole was initially identified in Anacor Pharmaceuticals’ chemical library and then optimized with Scynexis and Pace University. The example demonstrates how an existing chemical starting point can be transferred into a neglected-disease program and improved through collaboration. It does not support the broader claim that any old or “forgotten” compound is effective against a neglected disease. The molecule’s origin story appears in the 2025 annual report.
Comparing collaboration models
The following distinctions prevent very different projects from being lumped together under one label.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minute| Approach | Who contributes | What is contributed | What may be open | Typical stage represented |
|---|---|---|---|---|
| Open Synthesis Network | Chemistry teaching laboratories coordinated by DNDi; more than 20 institutions are cited | Design and synthesis of new compounds | Project participation and selected outputs; the cited description does not promise unrestricted release of every protocol or result | Compounds entering screening and lead work |
| Mycetoma Open Source | A community of researchers and partners around fungal mycetoma | Shared problem-solving, experiments and expertise | Transparent, community-driven collaboration; the cited summaries do not specify that every material or right is public | Discovery and development work; exact stage varies by activity |
| NTD Drug Discovery Booster | Participating pharmaceutical companies | Large-scale screening of company and public-domain libraries | Hit-compound commitments depend on the seed compound’s ownership and status | Primary screening and hit identification |
| Pathogen Box | Researchers receiving a shared collection assembled by Medicines for Malaria Venture | 400 compounds and follow-on testing | Free compound access, with public-domain data expected within two years | Screening and exploratory follow-up |
| Conventional internal program | One company or institution and its contracted partners | Private compounds, assays, chemistry and funding | Often limited by confidentiality and intellectual-property agreements | Any stage, depending on the program |
“Open” therefore needs a noun attached to it: open compounds, open protocols, open screening results, open data or open licensing. A project can be open in one dimension and restricted in another.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
What the screening totals do—and do not—tell you
Large numbers communicate search scale, not success rates. DNDi reports screening more than 3 million compounds for Leishmania and T. cruzi, plus 1.5 million for T. brucei. Those figures combine cumulative activity across programs and are not a count of approved medicines or even confirmed leads. The page does not state how many compounds survived each later filter.
A collection can contain duplicates, close chemical analogues or molecules unsuitable for human use. Conversely, a modest collection can produce a valuable lead if it reaches the right biological target and has a workable safety profile. The meaningful question is what happened after the initial hit: Was activity confirmed? Was selectivity demonstrated? Was the chemistry optimized? Did the program enter animal studies or clinical trials?
Historical cost figures need their labels
DNDi’s 2013 report supplied examples of development and implementation costs. They are historical, report-specific estimates and should not be compared as if they were current budgets or identical accounting categories.
| Program | Amount reported by DNDi in 2013 | How to interpret it |
|---|---|---|
| ASAQ development and implementation monitoring | EUR 12 million | Report-specific development and monitoring figure |
| NECT | EUR 6.8 million | Historical estimate for that program |
| SSG&PM | EUR 11.5 million | Historical estimate for that program |
| SCYX-7158 | EUR 38.3 million | Estimated development cost in the report |
| Fexinidazole | EUR 26.5 million | Estimated development cost in the report |
These examples illustrate why sharing can matter economically, but they do not prove that a particular crowdsourced model always costs less. Clinical development, manufacturing, regulatory work and access planning can dominate the budget after discovery chemistry is complete.
Benefits that are realistic—and limits that remain
Where distributed discovery helps
- More starting points: shared or repurposed collections expose neglected-disease teams to chemical matter they could not afford to assemble alone.
- Specialized capacity: teaching labs can synthesize compounds, companies can screen millions of molecules, and disease experts can interpret pathogen biology.
- Less duplication: sharing negative and positive results can reduce repeated testing of the same inactive molecules.
- Faster recognition of useful chemistry: a compound made for one purpose can be evaluated in another disease context, provided the new disease-specific evidence is generated.
- Training and field-building: networks bring additional chemists and biologists into diseases that attract fewer commercial programs.
Where it cannot substitute for standard development
- A hit may be an assay artifact or too toxic for patients.
- Activity against a pathogen in vitro does not establish a dose, route, durability or clinical benefit.
- Repurposing a known chemical does not remove the need for disease-specific efficacy and safety evidence.
- Open data can be delayed, incomplete or governed by agreements protecting pre-existing intellectual property.
- Manufacturing, formulation, regulatory review and equitable access still require money and specialized organizations.
How to evaluate a claim about a “forgotten” compound
Use this checklist before treating a headline as evidence of a new medicine:
- Name the exact compound. “An old drug” or “a library molecule” is not sufficiently precise.
- Identify the disease and organism. Activity against one parasite, fungus or bacterium cannot be transferred automatically to another.
- Ask what was measured. A biochemical target assay, cell assay, animal study and patient trial answer different questions.
- Separate hit, lead, candidate and treatment. The terms are stages, not synonyms.
- Check the date and source. DNDi’s screening totals are current-page cumulative figures without a stated publication year; the cost and neglected-disease share figures above come from a 2013 report.
- Look for the next gate. Confirmed activity, optimization, preclinical testing, clinical results and regulatory status should be stated separately.
The strongest account of crowdsourced discovery is therefore neither “the public found a cure” nor “old compounds are useless.” It is a description of how distributed contributors can enlarge the chemical search and improve the odds of finding a viable lead, while the proof burden for a safe and effective treatment remains unchanged.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
